Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Participants naïve to treatment with subcutaneous (SC) interferons or oral Disease Modifying Therapy (DMT) who are about to start PLEGRIDY PEN therapy will be screened for participation in this Phase IV trial. Participants will remain on Plegridy therapy as prescribed by their physician. Plegridy will not be provided to participants by Biogen as a part of this study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
RRMS patients naïve to treatment with SC interferon or oral and/or IV DMT for which PLEGRIDY is deemed necessary by the treating physician.
Patient willing and able to complete PSA and PAA questionnaires with minimal assistance.
You may not be if
Known allergy to any interferon or any component of peginterferon beta-1a.
Patients with hypersensitivity to Brimonidine topical gel.
Patients with other skin disorders.
History of previous treatment with Brimonidine tartrate.
